Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: A randomized, double-blind, multifactorial study

Journal of Human Hypertension

Volumn 27, Issue 5, 2013, Pages 321-327

  Littlejohn, T W ^a   Jones, S W ^b   Zhang, J ^c   Hsu, H ^c   Keefe, D L ^c  

^a Piedmont Medical Group   (United States)

^b Jones Family Practice   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aliskiren; amlodipine; calcium channel blocker; combination therapy; direct renin inhibitor; hypertension

Indexed keywords

ALISKIREN; ALISKIREN PLUS AMLODIPINE; AMLODIPINE; PLACEBO;

ABDOMINAL MASS; ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROENTERITIS; HAND FRACTURE; HEADACHE; HUMAN; HYDRONEPHROSIS; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PNEUMONIA; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URETER STONE;

ADULT; AGED; AMIDES; AMLODIPINE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RENIN;

EID: 84876096355     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2012.42     Document Type: Article

References (15)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
2. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
3. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24: 243-256.
4. Brown MJ, McInnes GT, Cherif PC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377: 312-320.
5. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
6. Hung HM. Evaluation of a combination drug with multiple doses in unbalanced factorial design clinical trials. Stat Med 2000; 19: 2079-2087.
7. Braun-Dullaeus RC, Zhang J, Hristoskova S, Haring DA, Liao W. First-line therapy with aliskiren/amlodipine combination provides robust blood pressure reductions in patients with moderate to severe hypertension. J Clin Hypertens 2010; 12(Suppl 1): abstract 27 PO-22.
8. Littlejohn III TW, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009; 25: 951-959.
9. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixeddose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407.
10. Shah NR, Hirsch AG, Zacker C, Wood GC, Schoenthaler A, Ogedegbe G et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens 2009; 22: 392-396.
11. Kettani FZ, Dragomir A, Cote R, Roy L, Berard A, Blais L et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213-220.
12. Perreault S, Dragomir A, White M, Lalonde L, Blais L, Berard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009; 266: 207-218.
13. Wu PH, Yang CY, Yao ZL, Lin WZ, Wu LW, Chang CC. Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens 2010; 23: 155-160.
14. Drummond W, Munger MA, Rafique EM, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens 2007; 9: 742-750.
15. Black HR, Weinberger MH, Purkayastha D, Lee J, Israel M, Hilkert R et al. Combination aliskiren/amlodipine is more effective than amlodipine monotherapy in male and female African American subjects with stage 2 hypertension. J Clin Hypertens 2010; 12(Suppl 1): abstract 26 PO-20.